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Summary
In the midgestation murine embryo, several major
vascular tissues contain hematopoietic stem cell (HSC)
activity. These include the aorta-gonad-mesonephros
region (AGM), yolk sac, and fetal liver. Recently, the
placenta was demonstrated to harbor hematopoietic
progenitors, but it was not examined for HSC activity.
We demonstrate here that the placenta also harbors
adult-repopulating HSCs. Placental HSCs begin to be
detected at embryonic day (E) 11, and HSC numbers
increase dramatically between E11 and E12, exceed-
ing the numbers in the circulating embryonic blood.
Furthermore, all placental HSC activity is restricted to
the GFP+ fraction of cells in Ly-6A (Sca-1) GFP trans-
genic embryos. Cells coexpressing GFP and endothe-
lial markers CD34 and CD31 are found in the embry-
onic vasculature of the placental labyrinth. Moreover,
placental cell expression of other HSC markers and
transcription factors suggests that HSC emergence
may occur in the placenta, as has been proposed for
other embryonic hematopoietic sites.
Introduction
For over 30 years, there has been a continuing debate
concerning the origin of definitive hematopoiesis in the
murine embryo. As the yolk sac (YS) is the first tissue
during development to produce blood cells (primitive
erythroid cells), it was assumed to be the sole source
of hematopoiesis in the mammalian embryo (Moore and
Metcalf, 1970). However, accumulating evidence pointed
to another anatomical site within the embryo as the
source of definitive hematopoietic cells. Avian and am-
phibian embryo grafting experiments demonstrated
that the adult hematopoietic system was derived pri-
marily from the embryonic part of the conceptus in a
mesodermal region containing the dorsal aorta and
pronephros (Chen and Turpen, 1995; Dieterlen-Lievre,
1975). More recent experiments in amphibian embryos
have confirmed these results and further demonstrate
that distinct blastomeres in the 32-cell stage give rise
to hematopoietic cells of the YS and embryo body
(Ciau-Uitz et al., 2000). In the mouse, it was more re-
cently shown that the first hematopoietic stem cells
(HSCs; cells fully competent to long-term reconstitute
the entire adult hematopoietic system after transplanta-
tion into irradiated, adult recipients) are autonomously
generated in the intraembryonic aorta-gonad-meso-
nephros (AGM) region, and more precisely the aorta-*Correspondence: e.dzierzak@erasmusmc.nlmesenchyme subregion at embryonic day (E) 10.5 (de
Bruijn et al., 2000; Medvinsky and Dzierzak, 1996;
Muller et al., 1994). While this is the first source of such
fully competent HSCs, other in vivo transplantation
scenarios (injection into the placenta or YS cavity of
embryos, injection into the liver of conditioned neonatal
recipients, or intravenous injection into immunodefi-
cient recipients) have revealed long-term repopulating
cells with multipotential hematopoietic properties at
earlier embryonic stages (Cumano et al., 2001; Toles et
al., 1989; Weissman et al., 1978; Yoder et al., 1997a,
1997b). Such multipotential cells were found in the YS
and paraaortic splanchnopleura (precursor tissue to
the AGM) at E8, E9, and E10. Hence, both the YS and
intraembryonic tissues are capable of generating hema-
topoietic cells, and it is as yet undetermined whether
cross-seeding of hematopoietic tissues occurs via the
circulation and whether tissue-specific maturation of
hematopoietic cells is required for the generation of the
adult hematopoietic system. Importantly, a recent de-
tailed quantitative analysis of HSC distribution in the
midgestation embryo suggests that the fetal liver is col-
onized from multiple sources, including the AGM and
YS (Kumaravelu et al., 2002).
In addition to the AGM and the YS, the allantois has
been identified as a third site of hematopoiesis in the
chick embryo (Caprioli et al., 1998). However, in murine
embryos, it is not yet clear whether the allantois is
hematopoietic (Downs and Harmann, 1997). The murine
allantois derives from the mesoderm at the posterior
end of the mouse embryo and makes contact with the
chorion at E8.5 (reviewed in Cross, 1998; Cross et al.,
2003a, 2003b; Han and Carter, 2001; Rossant and
Cross, 2001). The chorioallantoic placenta forms at this
junction, and, thereafter, the allantois contributes the
fetal vascular and associated stromal components, in-
cluding the umbilical vessels (Downs et al., 1998). Inter-
estingly, the placenta was recently demonstrated to
contain clonogenic hematopoietic progenitors, includ-
ing CFU-GMs, CFU-GEMMs, BFU-Es, and HPP-CFCs
(Alvarez-Silva et al., 2003). Moreover, between E10 and
E12, these progenitors were present at numbers higher
than those found in the YS and fetal liver. However, it
was not investigated whether the placenta also con-
tains HSCs.
A well-recognized feature shared by embryonic
hematopoietic sites is the associated development of
the vascular and hematopoietic systems. A wide range
of evidence has supported hemangioblasts and hemo-
genic endothelium as the presumptive precursors to
emerging hematopoietic cells (reviewed in Dieterlen-
Lievre, 1998; Nishikawa, 2001; Ottersbach and Dzier-
zak, 2005; see http://Eurekah.com for the online version
of this chapter). In Ly-6A GFP transgenic mice express-
ing the green fluorescent protein (GFP) under the regu-
latory elements of the HSC marker Sca-1, we demon-
strated that all HSC activity was confined to the GFP+
fraction in AGM, fetal liver, and adult bone marrow tis-
sues (de Bruijn et al., 2002; Ma et al., 2002). We further
showed by immunohistologic analysis of E9–E11 em-
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slayer of the dorsal aorta, the vitelline artery, and the
major blood vessels of the YS. The common expression f
1of this transgene, as well as other markers, in endothe-
lial cells and AGM HSCs highlights the close relation- s
pship between these two cell types and supports the
notion that HSCs derive from specialized “hemogenic” p
endothelial cells that are present for a brief period of
time during midgestation. P
In extending our analysis of these HSC marker trans- a
genic embryos to earlier times in development, E6– P
E7.5, we found high GFP expression restricted to extra- t
embryonic tissues: the ectoplacental cone and the t
extraembryonic ectoderm. Since these sites contribute i
to the placenta, the temporal expression was exam- o
inedin the placenta, beginning from E9, just after the d
fusion of the chorion and the allantois. At all stages c
examined, we found high-level GFP expression re- j
stricted to the embryonic/fetal vessels of the placental l
labyrinth (the layer of the placenta in which the embry- t
onic circulation comes into contact with the maternal o
circulation). This observation prompted us to test for t
HSC activity in the placenta. We show here that adult- 1
type HSCs are indeed present in the placenta, starting E
from E11, and that they are again exclusively found in (
the Ly-6A GFP+ fraction. Moreover, other HSC markers b
colocalize with GFP+ cells in the labyrinth region. These W
results suggest that the placenta, together with other m
distinct embryonic tissues, contribute to the adult hem- t
atopietic system. a
a
pResults
c
sExpression of Ly-6A GFP in the Highly
4Vascularized Tissues of the Embryo
rPreviously, we have shown that all HSCs in the AGM
oregion of the midgestation mouse embryo are localized
4to the Ly-6A GFP+ aortic fraction of cells (de Bruijn et
(al., 2002). GFP expression is found in some endothelial
ccells of the dorsal aorta, and an even stronger expres-
tsion is found in the endothelial cells lining the vitelline
cartery (Figure 1A). Hematopoietic clusters along the lu-
tmen of the aorta and vitelline arteries also contain GFP+
tcells (Figure 1B). Moreover, strong GFP expression is
tfound in the umbilical artery (Figure 1E) and the major
mvessels of the YS (de Bruijn et al., 2002). All these sites
pcontain potent HSC activity as determined by in vivo
ctransplantation into adult, irradiated recipients (de Bru-
eijn et al., 2000; Medvinsky and Dzierzak, 1996).
In addition to these known hematopoietic tissues, the
placenta is also highly vascularized, and, thus, we ex- A
wamined this tissue for expression of the Ly-6A GFP
marker. As the placenta is formed from both maternally W
mand embryonic-derived cells, the Ly-6A GFP transgene
was transmitted only through the male germline. Al- G
cready in the prestreak-stage embryo, high GFP expres-
sion is also found in the extraembryonic ectoderm and (
eectoplacental cone (Figures 1C and 1D). The highest
intensity of GFP expression is found where the extra- [
tembryonic ectoderm borders the primitive ectoderm. At
E7.25, the extraembryonic ectoderm remains GFP+ (
T(Figures 1F–1H). At this stage, the exocoelom is forming
and the extraembryonic ectoderm appears to be ad- aancing toward the GFP+ ectoplacental cone. Most
trikingly, at E12, high levels of GFP expression are
ound in the embryonic vessels of the placenta (Figure
I). Thus, similar to the other major hematopoietic tis-
ues in the embryo, the placental vasculature ex-
resses Ly-6A GFP, suggesting a potential for hemato-
oietic activity.
lacenta Contains Potent HSCs Beginning
t Midgestation
reviously, Alvarez-Silva et al. (2003) have found hema-
opoietic progenitor activity in the placenta. However,
he presence of HSC activity was not tested. To exam-
ne the placenta for potent, adult-engrafting HSCs, we
btained E9–E12 embryos (human b-globin transgenic),
issected the placenta (without the decidua or umbili-
al vessels), made a single-cell suspension, and in-
ected various doses of cells (placental tissue equiva-
ents) into irradiated, adult recipients. Engraftment was
ested by peripheral blood DNA PCR for the presence
f the donor (human b-globin) marker at 1 and greater
han 4 months posttransplantation. As shown in Table
, no engrafted mice were found after transplantation of
9 or E10 placenta cells. However, potent engraftment
greater than 10% donor cell contribution) was found
eginning at E11 and was present at high levels at E12.
e tested these recipients for multilineage engraft-
ent. High-level engraftment was observed in all hema-
opoietic tissues and in sorted myeloid, T lymphoid,
nd B lymphoid cells in recipients of E11 (not shown)
nd E12 placental cells (Figure 2A). Moreover, the trans-
lantation of the bone marrow from these primary re-
ipients into secondary, adult, irradiated recipients re-
ulted in similar high-level repopulation at greater than
months posttransplantation (six positive/six injected,
ange of repopulation: 75%–98%). Frequency analysis
f HSCs within the E12 placenta showed 1 HSC per
9,713 cells, with approximately 12 HSCs per placenta
as determined by Poisson statistics). Thus, the pla-
enta contains potent repopulating cells that fulfill all
he established functional criteria of HSCs. However, in
ontrast to the AGM, we found that HSC numbers in
he placenta were not expanded during an organ cul-
ure step (data not shown). This is most likely due to
he large size of the placenta (compared to the AGM),
aking it unsuitable for explant culture. Thus, while the
lacenta contains HSCs, it is uncertain whether the pla-
enta possesses the intrinsic ability to generate and
xpand HSCs.
ll Placental HSCs Are Contained
ithin the GFP+ Fraction
e next performed flow cytometric analysis to deter-
ine the number and phenotypic characteristics of
FP+ cells in the midgestation placenta. E12 placenta
ells were stained with antibodies specific for CD31
endothelial, macrophage and AGM HSC marker [North
t al., 2002]), CD34 (endothelial and AGM HSC marker
Sanchez et al., 1996]), c-kit (HSC and immature, hema-
opoietic progenitor marker [Sanchez et al., 1996]), CD45
pan-hematopietic marker [Morrison et al., 1997]),
er119 (erythroid progenitor marker [Kina et al., 2000]),
nd CD41 (hematopoietic progenitor and megakaryo-
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379Figure 1. Expression of Ly-6A GFP during Placental Development
(A–I) (A, B, and E) Fluorescent microscopic examination of cryosections, (C, D, F–H) whole embryos, and (I) whole placenta was performed.
(A) Transverse section through E11 Ly-6A GFP aorta and vitelline artery stained with anti-CD34 antibody. (B) Close-up view of hematopoietic
cluster (boxed area in [A]). (E) Transverse section through E10 Ly-6A GFP umbilical artery stained with anti-CD31 antibody. (C and D) (C)
Brightfield and (D) fluorescent light view of a whole prestreak E6 Ly-6A GFP conceptus. (F) Brightfield, (G) fluorescent, and (H) merged views
of a whole E7.25 Ly-6A GFP conceptus. (I) Coronal view of the embryonic face of an E12 Ly-6A GFP placenta showing the GFP fluorescence
in the umbilical artery and the embryonic vessels of the labyrinth. GFP, green fluorescence; CD31/CD34, red fluorescence; ee, extraembryonic
ectoderm; ec, ectoplacental cone; ua, umbilical artery; da, dorsal aorta; va, vitelline artery. In (A), ventral is down.cyte marker [Mikkola et al., 2003]). GFP+ cells (Figure
2B) were found to represent 3.09% of the total viable,
nucleated cell population (absolute number per pla-
centa = 1.8 × 104 GFP+ cells). No GFP+ cells were de-
tected in the maternally derived decidua (Figure 2C).
This was due to the paternal transmission of the
transgene and confirms the embryonic origins of GFP+
cells. In addition, when E12 decidua cells were trans-
planted, no HSC activity was detected (1 month post-
translation). Not surprisingly, the placenta is 36% ery-
throid, as determined by Ter119 staining (Figure 2H),
and appears to have a high endothelial cell content, as
judged by the fact that 40% of placental cells are
CD31+ (Figure 2D). However, CD31 also marks cells of
the trophoblast lineage (Cross et al., 2003a). Nonery-
throid hematopoietic cells make up 5.7%–7.6% of the
placenta (CD41- and CD45-positive cells; Figures 2I
and 2E, respectively). There is almost no overlap in
Ter119 and Ly-6A GFP expression. However, 7%, 13%,
15%, and 78% of the respective CD31+, c-kit+, CD45+,
and CD34+ populations are Ly-6A GFP+. Most interest-
ingly, 75%, 66%, and 56% of GFP+ cells express CD31,
c-kit (Figure 2F), and CD34 (Figure 2G), respectively.
Since AGM HSCs coexpress c-kit and CD34, wetested the overlap in expression of these markers with
GFP in placental cells. As shown in Table 2, over 50%
of GFP+ cells are c-kit+CD34+. Similarly, over 50% of
GFP+ cells are c-kit+CD31+, while lower percentages of
GFP+ cells are c-kit+CD41+ and c-kit+CD45+. This marker
distribution within the GFP+ placental cell population is
reminiscent of that observed for AGM HSCs (de Bruijn
et al., 2002) and, thus, suggests that at least some of
the placental GFP+ cells are HSCs.
To determine whether the placental HSC activity lies
within the GFP+ fraction of cells, we sorted GFP+ and
GFP− cells from E12 transgenic placentas. One and
0.25 placenta equivalents of cells were injected into ir-
radiated, adult recipients and were analyzed 1 and/or 4
months later for donor cell engraftment. As shown in
Table 1, all HSC activity was found in the GFP+ fraction.
These cells yielded high-level, long-term repopulation
and contributed to all hematopoietic lineages (not
shown). In addition, secondary transplantations of bone
marrow showed that GFP+ placental HSCs are selfre-
newing (four positive/six injected, 1 month posttrans-
plantation). Thus, all placental HSCs are Ly-6A GFP
expressing. However, since frequency analysis demon-
strates that there are only approximately 12 HSCs per
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380TTable 1. Adult-Repopulating HSC Activity in the Placenta at
Different Developmental Stages C
Number of Mice
Placenta Repopulated/Total Range of
Stage Equivalent Transplanted Repopulation G
GE9 2–4 0/3 0
E10 < 35 SP 3 0/2 0 G
G> 35 SP 1–3 0/4 0
E11 0.5–3 1/5 100% G
E12 1 3/3 15%–62% P
0.3 3/4 33%–61% d
0.1 3/6 48%–67% c
E12 GFP+ 1 3/6 28%–100% (
0.25 4/9 32%–100% s
E12 GFP− 1 0/6 0 e
0.25 0/8 0 a
Placentas were isolated from either human b-globin or from Ly-
6A GFP transgenic mice, dissected free of deciduas and umbilical
vessels, dissociated by collagenase treatment, and injected into
birradiated, adult recipients. The amount of injected material is
Cindicated in placenta tissue equivalents. At greater than 1 and/or 4
smonths, peripheral blood was collected and tested for the
presence of the donor marker by semiquantitative PCR. The o
number of repopulated mice (>10% donor contribution) per total e
number of injected mice is indicated with the corresponding c
percentages of repopulation. E, embryonic day; SP, somite pairs.
3
agenic placentas from E9 (not shown) and E10–E12 em- and CD34, CD41 shows a punctate expression pattern
Figure 2. Multilineage Analysis of Mouse Re-
constituted with Placenta-Derived HSCs and
Flow Cytometric Analysis of E12 Ly-6A GFP
Placental Cells
(A) DNA PCR multilineage contribution analy-
sis is shown for an adult, irradiated recipient
transplanted with 0.3 embryo equivalents of
E12 placenta cells (human b globin trans-
genic). Genomic DNA was obtained from
organs and sorted cell hematopoietic pop-
ulations at greater than 4 months post-
transplantation. DNA was analyzed for the
presence of the donor marker (b globin) by
semiquantitative PCR. The percentage of
donor contribution (along the bottom of the
panel) was calculated from the ratios be-
tween the donor marker and myogenin and
by comparison with a standard curve gener-
ated from control mixes of DNA ranging from
0% to 100% donor marker. PB, peripheral
blood; BM, bone marrow; Th, thymus; LN,
lymph node; Sp, spleen; M, sorted BM my-
eloid cells; E, sorted BM erythroid cells; L, sorted BM lymphoid cells; B, sorted spleen B lymphocytes; T, sorted spleen T lymphocytes.
(B–I) Dissociated cells from (B, D–I) E12 Ly-6A GFP transgenic placentas or (C) decidua were stained with phycoerythrin-conjugated antibodies
against CD31, CD45, c-kit, CD34, Ter119, and CD41 as indicated on the y axis. GFP fluorescence is shown on the x axis. Percentages for
each population are indicated inside the quadrants. Dead cells were excluded by gating out 7AAD-positive cells.able 2. Multicolor Flow Cytometric Analysis of E12 Placental
ells
Absolute
% of Total % of GFP+ Number/Placenta
FP+ 2.54 ± 0.47 15216 ± 2809
FP+c-kit+CD34+ 54.70 ± 11.27 7958 ± 1429
FP+c-kit+CD31+ 55.26 ± 16.74 8654 ± 3237
FP+c-kit+CD41+ 32.62 ± 7.43 5044 ± 1508
FP+c-kit+CD45+ 11.88 ± 2.32 1743 ± 424
lacentas were isolated from E12 Ly-6a GFP transgenic embryos,
issected free of deciduas and umbilical vessels, dissociated by
ollagenase treatment, and stained with c-kit-specific antibody
allophycocyanin conjugated) and CD34-, CD31-, CD41-, or CD45-
pecific antibody (phycoerythrin conjugated). Dead cells were
xcluded by 7AAD staining. GFP+ cells were gated and further
nalyzed for coexpression of the above-listed markers.o
E12 placenta, not all GFP+ cells are HSCs. These re- 3
sults are consistent with previous findings in the AGM d
region for GFP+ cells. e
a
oGFP+ Cells Localize to Vascular Labyrinth
Since flow cytometric analysis demonstrated that GFP+ l
ccells were distributed between the cell fractions char-
acterized by both endothelial and hematopoietic stem/ e
3progenitor markers, we took a temporal and spatial
immunostaining approach to examine the specific lo- v
acalization of these cells. We stained Ly-6A GFP trans-ryos (Figure 3) with antibodies specific for CD31,
D34, and CD41. For orientation purposes, we show a
chematic diagram of a transverse and coronal section
f the placenta (Figure 3P). Distinct differences in the
xpression patterns of the three surface markers were
learly observed in both coronal sections (Figures 3M–
O) and transverse sections (Figures 3A–3C, 3E–3G,
nd 3I–3K). CD31 is expressed in many cells of the
uter placenta spongiotrophoblast layer (Figures 3A–
C and 3M). It is highly expressed on the cells of the
ilated maternal blood vessels and at a lower level on
ndothelial cells in the labyrinth. It is also expressed by
few endothelial cells lining the vessels in the chori-
nic plate (Figure 3D). Expression begins in the outer
ayer at E9 and by E12 is found also in the inner pla-
enta, although at lower levels. CD34 is expressed
xclusively in the cells of the inner placenta (Figures
E–3G, 3N), where it seems to outline the embryonic
essels (Figure 3H). Expression is low at E9 and E10
nd increases thereafter. In complete contrast to CD31
Placental Hematopoietic Stem Cells
381Figure 3. Colocalization of Expression of Ly-6A GFP with CD31, CD34, and CD41
(A–P) Placentas from (A, E, and I) E10, (B, F, and J) E11, and (C, G, and K) E12 Ly-6A GFP embryos were cryosectioned at 10 m and stained
with antibodies against (A–C) CD31, (E–G) CD34, and (I–K) CD41. (P) A schematic view of a transverse (left) and coronal (right) section of
placenta. High magnification of vasculature and blood cells in Ly-6A GFP cryosections. (D) E12 section stained with anti-CD31 antibody. (H)
E11 section stained with anti-CD34 antibody. (L) E11 section stained with anti-CD41 antibody. Coronal sections of E12 Ly-6A GFP placentas
stained with (M) anti-CD31 antibody, (N) anti-CD34 antibody, and (O) anti-CD41 antibody. (A–C, E–G, I–K, M–O) Sections were analyzed by
confocal microscopy, and individual pictures (tiles) were assembled to display the entire structure. In the E10 panels, the intensity of the red
channel was enhanced to reveal placental morphology. The boundaries of the labyrinth and spongiotrophoblast regions in panels (A)–(C),
(E)–(G), and (I)–(K) are highlighted with dotted lines. Arrowheads indicate the embryonic vessels. Green, GFP; red, antibody stainings; s,
spongiotrophoblast layer; l, labyrinth.
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382mainly in the inner placenta (Figures 3I–3K, 3O), where (
eit predominantly marks cells within the blood vessels
(Figure 3L).
sIn situ hybridization was performed to localize c-kit-
expressing cells in the placenta, since high background t
Gstaining was observed with c-kit-specific antibodies.
As shown in Figure 4A, c-kit expression is found in t
amesenchymal cells of the chorionic plate (black arrow)
and in islands of mesenchymal cells in the labyrinth p
3(white arrows). Many of the vessels also contained
c-kit-expressing endothelial cells (arrowheads). We also G
tdetected expression in some trophoblast giant cellsFigure 4. Expression of c-kit in the E12 Placenta and Hematopoietic Transcription Factors in the E11 Placenta
(A) E12 placentas were cryosectioned at 10 m and hybridized with a riboprobe for c-kit. Shown is a 10× magnification of a transverse section;
the embryonic face of the placenta is oriented downward. c-kit expression is found in endothelial cells (arrowheads), and in mesenchymal cells
in the chorionic plate (black arrow), and in the labyrinth (white arrows).
(B–J) Placentas from (B–D) GATA2 LacZ, (E and F) GATA3lz/+, and (G–J) Runx1lz/+ E11 embryos were stained for β-galactosidase and cryosec-
tioned at 10 m. Sections were counterstained with hematoxylin and inspected by light microscopy. (B, E, and H–J) Transverse sections. (C,
D, F, and G) Coronal sections. Magnifications: (B and C) 4×, (G and H) 10×, (E and F) 20×, (D, I, and J) 40×. (D) is the boxed region in (C). (I)
and (J) are close-up views of the boxed areas in (H). Arrowheads indicate trophoblast giant cells, and arrows indicate cells underlying the
endothelium in a region in which cells may be budding into the lumen of the vessels. s, spongiotrophoblast layer; l, labyrinth; c, chorionic
plate; hc, hematopoietic cell; ec, endothelial cell.not shown). The expression of c-kit was highest on the
mbryonic face of the placenta.
The general expression pattern of Ly-6A GFP is very
imilar to that of CD34, as expected from the results of
he flow cytometric analysis (78% of CD34+ cells are
FP+). Expression begins at E9 in some of the cells of
he labyrinth and increases thereafter. GFP+ cells are
lso found lining the fetal blood vessels in the chorionic
late and in the umbilical vessel (arrowheads in Figures
A and 3E). Most of the overlap in the expression of
FP with CD34 is in the labyrinth region (Figure 3F) in
he endothelial cells lining the fetal vessels that form a
Placental Hematopoietic Stem Cells
383network through this region. There appears to be only a
small amount of overlap of CD31 with GFP-expressing
cells, confirming flow cytometric data (only 7% of
CD31+ cells are GFP+). These cells are found in the
large embryonic vessels within the chorionic plate and
also in the umbilical artery (Figures 3A and 3D and Fig-
ure 1E). We observed no overlap in the expression of
CD41 and GFP (Figures 3J and 3L). Thus, these im-
munostaining and in situ transcription results taken to-
gether with the multicolor flow cytometric analysis and
the finding that all HSCs are GFP+ strongly suggest that
placental HSCs are localized within the endothelium of
the embryonic vessels in the chorionic and labyrinth re-
gions.
Placental Embryonic Vessel Endothelium Expresses
Hematopoietic Transcription Factors
To further explore whether HSCs in the placenta may
be generated in situ, we examined the expression
pattern of three hematopoietic transcription factors,
GATA2, GATA3, and Runx1, known to be important for
HSC/progenitor development. Briefly, embryos defi-
cient for GATA2 die at E10.5, display severe anemia,
and lack HSCs (Tsai et al., 1994). A haploid dose of
GATA2 results in defective HSC expansion in the AGM
(Ling et al., 2004). The disruption of the related tran-
scription factor GATA3 leaves YS erythropoiesis largely
unaffected, but results in defective fetal liver hemato-
poiesis, as demonstrated by a reduction in hematopoi-
etic colony formation (Pandolfi et al., 1995). Runx1 defi-
ciency results in E12.5 lethality, fetal liver anemia, and
an absence of HSCs (Okuda et al., 1996; Wang et al.,
1996). A haploid dose of Runx1 disrupts the normal
pattern of HSC emergence in the embryo (Cai et al.,
2000).
We obtained E11 GATA2 lacZ, GATA3 lacZ, and
Runx1 lacZ embryos and stained and sectioned the
placentas. GATA2 lacZ embryos carry a lacZ reporter
transgene that recapitulates the endogenous GATA2
gene expression pattern (Zhou et al., 1998). GATA3 lacZ
and Runx1 lacZ embryos contain an endogenous gene-
targeted lacZ reporter (North et al., 1999; van Door-
ninck et al., 1999).
The expression pattern of all three transcription
factors differed. In GATA2 lacZ transgenic placental
sections, we found some expression in trophoblast gi-
ant cells, as reported previously (arrowhead in Figure
4B). However, higher levels of β-galactosidase staining
were found in the labyrinth (Figures 4B and 4C). An
increasing intensity of staining was observed toward
the fetal side of the placenta, especially on the borders
of the labyrinth region with the chorionic plate. GATA2
is expressed in some endothelial cells and in the un-
derlying cells that surround the fetal blood vessels (Fig-
ure 4D). Like GATA2, GATA3 is expressed in the tropho-
blast giant cells, although to higher levels (Figures 4E
and 4F, arrowheads). In contrast to GATA2, GATA3 ex-
pression is restricted to only these few cells at the fetal-
maternal interface. This pattern of expression confirms
the previous pattern seen by others using in situ tran-
scription analysis (Ng et al., 1994). The endothelial ex-
pression of GATA2 (but not GATA3) is reminiscent of the
expression of GATA2 at the onset of HSC emergencein the midgestation aorta (Minegishi et al., 1999; Zhou
et al., 1998).
Runx1 expression appears to localize to cells within
the blood vessels of the labyrinth (in the circulation, as
well as cells attached to the lumenal side of the endo-
thelium), to endothelial cells (Figures 4H–4J), and to
cells located just underneath the endothelium (arrows
in Figure 4I). Occasionally, we see clusters of β-galacto-
sidase-positive cells within the circulation or attached
to the endothelium. There also seems to be an accumu-
lation of positive cells in the chorionic plate (Figure 4G).
These Runx1-expressing cells are located both within
the walls of the vessels and surrounding the major
blood vessels at their junction with the umbilical ves-
sels (Figure 4G). Thus, the distribution of Runx1-
expressing cells amongst hematopoietic, endothelial,
and mesenchymal cells is similar to what has been re-
ported for Runx1-expressing cells in the AGM and sug-
gests that Runx1 may also be involved in the genera-
tion of HSCs in the placenta (North et al., 1999; North
et al., 2002).
Discussion
We have shown here that the placenta, a highly vascu-
larized tissue necessary for the exchange of oxygen
and nutrients between the embryo and the mother, con-
tains potent, adult-repopulating HSCs. These are not ma-
ternally derived HSCs, but are derived from the concep-
tus, as evidenced by the presence of the human b-globin
and Ly-6A GFP transgenic markers. They are as potent
as HSCs derived from the adult bone marrow in that they
give rise to long-term, high-level (15%–100%), multilin-
eage hematopoietic engraftment of irradiated, adult re-
cipients. Placental HSCs are also selfrenewing, since
they can repopulate secondary recipients. These data
now raise the possibility that, along with the AGM and
YS, the placenta may be an additional generating
source of HSCs that sequentially migrate and colonize
the fetal liver and bone marrow (Figure 5).
The Placenta as a Reservoir for Expanding
HSCs or for Their Generation?
Our transplantation data show that prior to E11, placen-
tal HSC activity appears to be limiting. We found no
HSCs in the placenta at E9 or E10. At E11, only one
out of five transplanted recipients receiving two tissue
equivalents of placental cells is HSC engrafted. At E12,
we found 12 HSCs per placenta. In more recent experi-
ments (not shown), we found that HSC numbers in the
placenta begin to decrease at E13 and disappear there-
after. Thus, the numbers of HSCs in the placenta
increase rapidly with developmental time and peak at
E12–E13. Indeed, large numbers of immature progeni-
tors have been found previously in the placenta and
greatly exceed the numbers found in the fetal liver (Al-
varez-Silva et al., 2003). Others have shown that the
human placenta secretes hematopoietic growth factors
that stimulate hematopoietic colony formation (Bur-
gess et al., 1977). More recent work demonstrates that
mesenchymal progenitor cells isolated from the human
placenta can expand long-term, culture-initiating cells
from cord blood (Zhang et al., 2004). Hence, the he-
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Figure 5. HSC Dissemination during Development
Model for HSC generation and migration. HSCs may be generated h
and/or expanded in up to three different anatomical sites during C
mouse development: YS, AGM, and placenta. Some cross-seeding
imay occur between these sites via the circulation (dashed arrows).
sHSCs from all three sources may be needed to colonize the fetal
liver (curved, solid arrows), which remains the main location of he- s
matopoiesis until birth, when hematopoiesis permanently relocates a
to the bone marrow for the entire adult life. t
c
bmatopoietic growth capacity of the placenta is enor-
fmous, and it is not surprising that it is a potent hemato-
npoietic microenvironment for HSCs.
sRecently, quantitative data on the numbers of HSCs
fpresent in the various hematopoietic tissues and circu-
rlation in the midgestation mouse have been presented.
iKumaravelu et al. (2002) found that at E12 there are 3.2
tHSCs in circulation. Correcting for numbers of HSCs in
mtissues due to circulation, the AGM was found to con-
ptain 2.7 HSCs, the YS 1.8, the liver 53, and the umbilical
cord 0.8. Given that the E12 placenta contains 12 HSCs
(four times more HSCs than in the whole of the embry- A
ionic blood), and considering that the fetal liver contains
53 HSCs at E12, it is highly likely that the placenta is a P
hpotent HSC contributor to the colonization of the fetal
liver, along with the AGM and YS. a
fIt is as yet uncertain whether the HSCs in the pla-
centa are intrinsically or extrinsically generated. If the t
oplacenta was found to contain HSCs at E10 or earlier,
it would implicate the placenta as the first site of emer- h
pgence of HSCs in the mouse embryo. Previously, to de-
tect the onset of HSC activity in the E10 AGM region, it c
lwas necessary to transplant 96 adult recipients with a
total of 112 AGM tissue equivalents of cells to observe a
tthe long-term, high-level, multilineage repopulation of
3 recipients (Muller et al., 1994). Given the limited q
fnumber of mice transplanted with E10 placental cells
in this study, it remains a possibility that the placenta c
Ncontains HSCs at this earlier time point. To address the
issue of autonomous generation, we performed explant t
scultures with whole placentas. While we could maintain
HSCs in AGM explants, no HSCs could be maintained
pin placentas. Thus, the origins of the HSCs in the pla-
centa are unclear and await the results of lineage-mark- p
ting approaches.
v
pAssociation of Placental HSCs and the Vasculature
The strong association of hematopoietic and endothe- i
plial markers on the earliest hematopoietic cells in theouse embryo, including HSCs, prompted our studies
n the placenta. The Ly-6A GFP transgenic marker was
ound to be expressed in the endothelial cells lining the
ajor vessels of the placenta. Moreover, all HSC activ-
ty was attributed to the GFP+ fraction of the placenta.
hus, consistent with previous data, the Ly-6A GFP ex-
ression again marks all HSCs. While the number of
FP+ cells in the placenta far exceeds the number of
SCs, other markers (such as CD34, CD31, c-kit, etc.)
ere used to further localize placental HSCs. Previous
tudies on the AGM have shown that all AGM HSCs are
-kit+CD34+ (Sanchez et al., 1996) and CD31+ (North et
l., 2002). Our multicolor flow cytometric analysis
trongly suggests that placental HSCs are GFP+c-kit+
D34+.
Immunostaining of Ly-6A GFP transgenic placentas
as further supported the notion that these HSCs are
D34+. CD34- and GFP-coexpressing cells were found
n the labyrinth region. This highly vascularized region
howed coexpressing cells lining the embryonic ves-
els. Similarly, although at a lower frequency, CD31-
nd GFP-coexpressing cells were also found in endo-
helial cells lining the vessels of the labyrinth. Moreover,
-kit expression was found in a few cells in this region
y in situ transcription analysis. In no sections did we
ind prominent hematopoietic clusters with these phe-
otypic characteristics. However, we did observe rare
ingle GFP+ cells adhering closely to the lumenal sur-
ace of the larger vessels. Thus, in analogy to the AGM
egion in which GFP and CD34/CD31 are coexpressed
n the ventral aortic endothelial cells and some cells of
he associated hematopoietic clusters, these markers
ay also indicate associations of these two lineages in
utative hemogenic endothelium of the placenta.
Role for Transcription Factors GATA2 and Runx1
n Placental Hematopoiesis?
reviously, it was reported that GATA2 and GATA3 are
ighly expressed in the placenta in the trophoblast gi-
nt cells positioned at the embryonic-maternal inter-
ace during midgestation (Ng et al., 1994). The GATA
ranscription factors regulate the expression of a number
f trophoblast-specific genes, such as the prolactin
ormone placenta lactogen I and the angiogenic factor
roliferin (Ma et al., 1997; Ng et al., 1994). These mole-
ules appear to play an important role in the neovascu-
arization of the placenta in the interface region (Ma et
l., 1997). We also found expression of these transcrip-
ion factors in trophoblast giant cells. The lower fre-
uency of GATA3- expressing trophoblast cells that we
ound most likely was a reflection of a haploinsuffi-
iency of GATA3 due to a defective targeted allele.
onetheless, GATA3 was restricted in its expression to
hese cells and is known to rapidly decline in its expres-
ion after E10 (Ng et al., 1994).
GATA2 had a much more widespread expression
attern than previously described. GATA2 was ex-
ressed in some endothelial cells lining the vessels of
he labyrinth, as well as in many cells surrounding the
essels. The intensity of expression increased with
roximity to the chorionic plate of the placenta. At the
nterface of the labyrinth region with the chorionic
late, GATA2 expression was the highest. Thus, GATA2
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rinth by regulating the expression of angiogenic factors.
Additionally, it may also be involved in the generation
and/or proliferation of HSCs from hemogenic endothe-
lial cells in the labyrinth.
Previously, the expression of Runx1 in the placenta
was found by RT-PCR (Alvarez-Silva et al., 2003), but
its expression pattern within the placenta was not ex-
plored. As one of the most important HSC transcription
factors, Runx1 is required for the emergence of HSCs
in the midgestation embryo and is expressed in aortic
hematopoietic clusters, endothelial cells, and under-
lying mesenchymal cells (North et al., 1999). The ex-
pression pattern of Runx1 lacZ in the placenta is
reminiscent of this pattern. We found high-level Runx1-
expressing cells in the lumen of the labyrinth vascula-
ture as well as in some of the endothelial cells lining
the vessels. Lower-level expressing cells were found
underlying some of the endothelium. Thus, as in the
AGM region, Runx1 is most likely playing a role in the
emergence of HSCs. We are currently testing E12 pla-
centas from Runx1+/− and Runx1−/− embryos for HSC
activity in transplantation assays.
Finally, we have also investigated the possible role of
the oncogene c-fos in placental HSC generation. High
levels of c-fos have previously been observed in the
placenta (Muller et al., 1983), and a placental defect in
c-fos−/− embryos has been suggested on the basis of
lower placenta weight, although no conclusive evi-
dence had been provided (Johnson et al., 1992). We
transplanted E12 placentas from c-fos−/− embryos and
found some low-level HSC activity still present (data
not shown). However, a more detailed analysis is re-
quired to unveil possible subtle differences in HSC fre-
quency between wild-type and c-fos−/− placentas.
In summary, we have found that the placenta is a
highly hematopoietic tissue, supporting the growth
and/or emergence of HSCs. As found by flow cytomet-
ric and histologic analysis, it appears to possess hemo-
genic endothelium, and we will test this in future experi-
ments. Notwithstanding, this may be taken as another
example of the recurring theme of HSC development
within the major vasculature of the embryo and may
indicate that the Ly-6A GFP transgene serves as a use-
ful marker for hemogenic endothelium in the embryo.
Thus, our results now add the placenta to the list of
embryonic tissues that contain HSCs (Figure 5), and we
propose that it plays an important role in the long-term
development of the adult hematopoietic system and
the colonization of the bone marrow with HSCs.
Experimental Procedures
Embryo Generation
Timed matings were set up between male Ly-6A GFP (de Bruijn et
al., 2002) or line 72 human b-globin (Strouboulis et al., 1992) trans-
genic mice and wild-type (C57BL/10 × CBA)F1 females; between
male transgenic GATA-2 YAC d16Z mice (Zhou et al., 1998) and
wild-type C57BL/6 females; and between male knockin Cbfa2lz/+
(North et al., 1999) or GATA-3lz/+ mice and (C57BL/10 × CBA)F1
females. The day of vaginal plug detection was considered as em-
bryonic day 0. For embryo generation, the transgene was always
inherited through the male parent in order to avoid contribution by
genetically marked maternal cells in transplantation assays. Ani-
mals were housed according to institutional guidelines, with freeaccess to food and water. Animal procedures were carried out in
compliance with the Standards for Humane Care and Use of Labo-
ratory Animals.
Cell Preparations
Pregnant mice were killed by cervical dislocation. Placentas were
dissected (free of umbilical cord and maternal decidua) and treated
for 1.5 hr at 37°C with 0.125% type I collagenase (SIGMA-ALDRICH
CHEMIE Gmbh, Germany) in PBS supplemented with 10% fetal calf
serum and penicillin/streptomycin. Cells were dispersed, washed,
and resuspended either in PBS for transplantation or in PBS sup-
plemented with 10% fetal calf serum and penicillin/streptomycin
for cell sorting or flow cytometric analysis. In some cases, ficoll
gradients (Lymphoprep, Axis-Shield, Oslo, Norway) were used to
remove the large number of erythroid cells present in placental
preparations prior to cell sorting.
Analysis of Long-Term, Multilineage Repopulating Activity
The presence of definitive HSCs in placental cell suspensions was
determined by intravenous injection into irradiated, adult recipients
as described previously (de Bruijn and Dzierzak, 2002). Recipient
(C57BL/10 × CBA)F1 males or females received a split radiation
dose of 900 rad from a 137Cs source. To ensure short-term survival,
2 × 105 adult (C57BL/10 × CBA)F1 spleen cells were coinjected.
One and/or 4 months posttransplantation, peripheral blood DNA
samples were analyzed for donor cell contribution by PCR as de-
scribed previously (de Bruijn and Dzierzak, 2002; de Bruijn et al.,
2002). For Poisson statistical analysis, the number of total cells
injected (x axis) was plotted against the percentage of mice nega-
tive for repopulation (y axis). The resulting straight line had a gradi-
ent of y = 100e−2E−05×. The frequency of HSCs is by definition deter-
mined at 37% of negative mice. In E12 placenta, the frequency of
HSCs was calculated to be 1 in 49,713 cells and, thus, 12 HSCs
per E12 placenta (6 × 105 nucleated cells per placenta).
For the analysis of multilineage repopulation, thymus, lymph
nodes, bone marrow, spleen, and peripheral blood samples were
collected from repopulated animals, DNA was isolated, and donor
contribution was assessed by PCR. Cells of the T, B, erythroid, and
myeloid lineages were sorted by using a combination of antibodies
listed below, and the DNA was analyzed for the presence of donor
markers. A total of 2–3 × 106 cells from the bone marrow of repopu-
lated mice were injected into secondary recipients to assess selfre-
newal capacity.
Cell Sorting and Flow Cytometry Analysis
All antibody stainings were carried out in a volume of 100–200 l
in PBS/10% fetal calf serum on ice for 30 min with the following
antibodies (PharMingen): anti-CD4-PE (clone GK1.5), anti-CD8a-PE
(clone 53-6.7), anti-CD31-PE (clone MEC 13.3), anti-B220-FITC
(clone RA3-6B2), anti-Ly6C-FITC, anti-Ter119-PE (clone TER-119),
anti-CD45-PE (clone 30-F11), anti-CD34-PE (clone RAM34), anti-c-
kit-PE (clone 2B8), anti-c-kit-APC (clone 2B8), anti-CD41-PE (clone
MwReg30), anti-Gr-1-PE (clone RB6-8C5), and anti-Mac1-PE (clone
M1/70). Just before analysis, 7AAD (7-aminoactinomycin D, Molec-
ular Probes, Leiden, NL) was added to allow live/dead cell discrimi-
nation. Cells were sorted on a FACSVantage (BD Biosciences), and
analysis was carried out on a FACScan (BD Biosciences). For single
and double antibody-stained samples of Ly-6A GFP placental cells,
5 × 104 and 1 × 106 events, respectively, were analyzed on the flow
cytometer, and CellQuest (BD Biosciences) was used for data pre-
sentation.
Immunohistochemistry and Confocal Microscopy
Dissected placentas were fixed for 1–2 hr, rotated in 2% parafor-
maldehyde/PBS at 4°C, and equilibrated overnight in 30% sucrose/
PBS at 4°C. Fixed tissues were embedded in Tissue Tek and quick-
frozen on dry ice, and 10 m cryosections were prepared. Immuno-
histochemical stainings were carried out as previously described
(de Bruijn et al., 2002) by using biotin-conjugated anti-CD31 (clone
MEC13.3; PharMingen), biotin-conjugated anti-CD34 (clone RAM34;
PharMingen), purified anti-CD41 (clone MWReg30; PharMingen),
biotin-conjugated anti-rat IgG1 (clone RG11/39.4; PharMingen),
and Streptavidin-Cy5 (Rockland Immunochemicals, Inc., Gilberts-
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m
In Situ Hybridization C
A 300 bp product was obtained by RT-PCR with E12 placenta a
RNA and mouse c-kit-specific primers 5#-AAGTGTACCCCGTAGAC t
AGG-3# and 5#-TGGTGTGGCCCCTTAAGTAC-3# (region 4397–4797 m
of accession number NM 021099), and cloned into the p-GEM-T
C
Easy vector (Promega). Digoxigenin-labeled riboprobes were pre-
L
pared by in vitro transcription by using a DIG RNA Labeling Kit
t
(Roche). Tissues were fixed in 4% paraformaldehyde/30% sucrose/
1
PBS at 4°C overnight, submerged in Tissue-Tek (Sakura Finetek,
CThe Netherlands), and quick-frozen on dry ice. 10 m sections
pwere prepared; treated with 100 mM Glycine in PBS for 10 min at
2room temperature, 0.3% Triton X-100 in PBS for 15 min at room
temperature, 1 g/ml Proteinase K in TE for 30 min at 37°C; and C
fixed in 4% paraformaldehyde/PBS for 5 min at 4°C. Sections were o
then acetylated (13% v/v triethanolamine, 0.175% v/v hydrochloric C
acid, 0.25% v/v acetic acid) for 10 min at room temperature and m
incubated for 1 hr at room temperature in hybridization buffer (50%,
C
5× SSC, 1× Denhardt’s, 0.1% Tween-20, 250 g/ml yeast t-RNA,
S500 g/ml salmon sperm DNA). Probes were diluted 100 pg in 100
d
l hybridization buffer, denatured for 5 min at 80°C, and incubated
Cwith the sections overnight at 65°C. After extensive washing with
t0.2× SSC, slides were blocked with 10% heat-inactivated sheep
Nserum in 0.1 M Tris (pH 7.5)/0.15 M NaCl all day at room temper-
ature and incubated overnight with alkaline phosphatase-conju- C
gated anti-digoxigenin antibody (1:4000, Roche) at 4°C. Sections (
were then incubated with 2% NBT/BCIP solution (Roche) in 0.1 M i
Tris (pH 9.5)/0.1 M NaCl/50 mM MgCl2/0.24 mg/ml levamisole at t
room temperature for 1 day. Slides were washed with TE and water, d
and the sections were fixed with 4% paraformaldehyde for 30 min h
at room temperature, washed with TE and water, and mounted with l
Aquamount (BDH). C
dLacZ Stainings
DDissected placentas were rinsed in PBS/0.02% NP40 and fixed at
a4°C for 1 hr with 10% Formal Saline/0.2% Glutaraldehyde/2 mM
dMgCl2/5 mM EGTA/0.02% NP40 (all in PBS). Tissues were then
awashed three times for 30 min per wash at room temperature with
ePBS/0.02% NP40 and stained overnight at room temperature with
15 mM K3Fe(CN)6/5 mM K4Fe(CN)6/2 mM MgCl2/0.01% Nade-
oxycholate/0.02% NP40/0.1% X-gal (all in PBS). The next day, tis- D
sues were washed five times with PBS and fixed, frozen, and sec- i
tioned as described above. M
D
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